<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">perinatology</journal-id><journal-title-group><journal-title xml:lang="ru">Российский вестник перинатологии и педиатрии</journal-title><trans-title-group xml:lang="en"><trans-title>Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1027-4065</issn><issn pub-type="epub">2500-2228</issn><publisher><publisher-name>Ltd. “The National Academy of Pediatric Science and Innovation”</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">perinatology-141</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>АЛЛЕРГОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ALLERGOLOGY</subject></subj-group></article-categories><title-group><article-title>Содержание антимикробных пептидов в сыворотке у детей с атопическим дерматитом</article-title><trans-title-group xml:lang="en"><trans-title>Serum levels of antimicrobial peptides in children with atopic dermatitis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ермолаева</surname><given-names>Е. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Ermolaeva</surname><given-names>E. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>асп. отделения иммунологии и клинической иммунологии НИКИ педиатрии РНИМУ им. Н.И. Пирогова</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Виноградова</surname><given-names>Т. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Vinogradova</surname><given-names>T. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н., в.н.с. лаборатории общей патологии того же учреждения 125412 Москва, ул.Талдомская, д. 2</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Пампура</surname><given-names>А. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Pampura</surname><given-names>A. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., рук. указанного отделения</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ОСП «Научно-исследовательский клинический институт педиатрии» ГБОУ ВПО РНИМУ им. Н.И. Пирогова, Москва</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Research Clinical Institute of Pediatrics, N.I. Pirogov Russian National Research Medical University, Moscow</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2015</year></pub-date><pub-date pub-type="epub"><day>13</day><month>03</month><year>2016</year></pub-date><volume>60</volume><issue>4</issue><fpage>89</fpage><lpage>92</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Ltd. “The National Academy of Pediatric Science and Innovation”, 2016</copyright-statement><copyright-year>2016</copyright-year><copyright-holder xml:lang="ru">Ltd. “The National Academy of Pediatric Science and Innovation”</copyright-holder><copyright-holder xml:lang="en">Ltd. “The National Academy of Pediatric Science and Innovation”</copyright-holder><license xlink:href="https://www.ped-perinatology.ru/jour/about/submissions#copyrightNotice" xlink:type="simple"><license-p>https://www.ped-perinatology.ru/jour/about/submissions#copyrightNotice</license-p></license></permissions><self-uri xlink:href="https://www.ped-perinatology.ru/jour/article/view/141">https://www.ped-perinatology.ru/jour/article/view/141</self-uri><abstract><p>Цель работы: установить взаимосвязь уровня циркулирующих антимикробных пептидов — кателицидина (LL-37), альфа-дефензинов (HNP 1-3) в сыворотке крови с клиническими проявлениями атопического дерматита у детей. В исследование были включено 70 пациентов в возрасте от 5 мес до 17 лет с атопическим дерматитом. Уровень LL-37 и HNP1-3 определяли с помощью иммуноферментного анализа. По результатам исследования уровень HNP1-3 был выше у детей со средней тяжестью заболевания в сравнении с детьми с легкой степенью атопического дерматита. Концентрация LL-37 в сыворотке крови не зависела от индекса тяжести дерматита SCORAD. Однако уровень этого пептида был связан с выраженностью отдельных клинических проявлений заболевания. Концентрация LL-37 была повышена при площади поражения более 50% поверхности тела; уровень LL-37 возрастал с увеличением интенсивности экскориаций, лихенификации и зуда. В то же время по мере нарастания интенсивности корок/мокнутия от легкой до умеренной степени уровень LL-37 увеличивался и резко снижался при максимальной ее выраженности. Установленная взаимосвязь между концентрацией антимикробных пептидов и клиническими проявлениями атопического дерматита свидетельствует о патогенетической роли LL-37 и HNP1—3 в развитии данного заболевания.</p></abstract><trans-abstract xml:lang="en"><p>Objective: to establish a relationship of the serum levels of the antimicrobial peptides (AMP) cathelicidin (LL-37) and a-defensins (HNP 1-3) to the clinical manifestations of atopic dermatitis (AD) in children. Subjects and methods. The investigation enrolled 70 patients aged 5 months to 17 years with AD. LL-37 and HNP1-3 levels were determined by enzyme immunoassay. Results. The level of HNP 1-3 was found to be higher in children with moderate AD than in those with its mild form. The serum concentration of LL-37 was independent of the severity scoring of atopic (SCORAD) index. However, the level of this peptide was associated with the magnitude of clinical manifestations of the disease. The concentration of LL-37 was increased with an injury over 50% of the body surface; its level rose with the higher intensity of excoriations, lichenification, and pruritus. At the same tone, as the intensity of crusts/oozing lesion increased from mild to moderate, LL-37 rose and drastically decreased at their highest intensity levels. Conclusion. The established correlation between AMP concentration and clinical manifestations of AD suggests that LL-37 and HNP1-3 play a role in the pathogenesis of this disease.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>дети</kwd><kwd>атонический дерматит</kwd><kwd>кателицидин</kwd><kwd>дефензины</kwd><kwd>SCORAD.</kwd></kwd-group><kwd-group xml:lang="en"><kwd>children</kwd><kwd>atopic dermatitis</kwd><kwd>cathelicidin</kwd><kwd>defensins</kwd><kwd>SCORAD.</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Boguniewicz M. Leung D. Y. Recent Insights into Atopic Dermatitis and Implications for Management of Infectious Complications. J Allergy Clin Immunol 2010 ; 125: 1: 4—13.</mixed-citation><mixed-citation xml:lang="en">Boguniewicz M. Leung D. Y. Recent Insights into Atopic Dermatitis and Implications for Management of Infectious Complications. J Allergy Clin Immunol 2010 ; 125: 1: 4—13.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">OngP.Y., Leung D.Y. The infectious aspects of atopic dermatitis. Immunol Allergy Clin North Am 2010; 30: 3: 309-321.</mixed-citation><mixed-citation xml:lang="en">OngP.Y., Leung D.Y. The infectious aspects of atopic dermatitis. Immunol Allergy Clin North Am 2010; 30: 3: 309-321.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">OngP. Y., Patel M., Ferdman R.M. et al. Association of staphy-lococcal superantigen-specific IgE with mild and moderate atopic dermatitis. JPediat 2008; 153: 6: 803-806.</mixed-citation><mixed-citation xml:lang="en">OngP. Y., Patel M., Ferdman R.M. et al. Association of staphy-lococcal superantigen-specific IgE with mild and moderate atopic dermatitis. JPediat 2008; 153: 6: 803-806.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Цывкина Е.А., Феденко E.C., Будихина A.C., Пинегин Б.В. Оценка уровня антимикробных пептидов (а-дефен-зинов) в лейкоцитах периферической крови больных атопическим дерматитом и пиодермией. Рос аллер-гол журн 2010; 5: 43—47. (Tsyvkina E.A., Fedenko E.S., Budikhina A.S., Pinegin B.V. Assessment of antimicrobial peptides (alpha-defensins) in atopic dermatitis and pyodermia patients blood. Rus Ros allergol zhurn 2010; 5: 43—47.)</mixed-citation><mixed-citation xml:lang="en">Цывкина Е.А., Феденко E.C., Будихина A.C., Пинегин Б.В. Оценка уровня антимикробных пептидов (а-дефен-зинов) в лейкоцитах периферической крови больных атопическим дерматитом и пиодермией. Рос аллер-гол журн 2010; 5: 43—47. (Tsyvkina E.A., Fedenko E.S., Budikhina A.S., Pinegin B.V. Assessment of antimicrobial peptides (alpha-defensins) in atopic dermatitis and pyodermia patients blood. Rus Ros allergol zhurn 2010; 5: 43—47.)</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Selsted M.E., OuelletteA.J. Mammalian defensins in the antimicrobial immune response. Nat Immunol 2005; 6: 551—557.</mixed-citation><mixed-citation xml:lang="en">Selsted M.E., OuelletteA.J. Mammalian defensins in the antimicrobial immune response. Nat Immunol 2005; 6: 551—557.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Zaiou M., Gallo R.L. Cathelicidins, essential gene-encoded mammalian antibiotics. J Mol Med (Berl) 2002; 80: 549-561.</mixed-citation><mixed-citation xml:lang="en">Zaiou M., Gallo R.L. Cathelicidins, essential gene-encoded mammalian antibiotics. J Mol Med (Berl) 2002; 80: 549-561.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol 2003; 3: 710-720.</mixed-citation><mixed-citation xml:lang="en">Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol 2003; 3: 710-720.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Witte M.B., Barbul A. General principles of wound healing. Surg Clin North Am 1997; 77: 3: 509-528.</mixed-citation><mixed-citation xml:lang="en">Witte M.B., Barbul A. General principles of wound healing. Surg Clin North Am 1997; 77: 3: 509-528.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">De Y, Chen Q., Schmidt A.P. et al. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl pep tide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. JExp Med 2000; 192: 1069-1074.</mixed-citation><mixed-citation xml:lang="en">De Y, Chen Q., Schmidt A.P. et al. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl pep tide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. JExp Med 2000; 192: 1069-1074.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Soehnlein O., Kai-Larsen Y, Frithiof R. et al. Neutrophil primary granule proteins HBP and HNP1-3 boost bacterial</mixed-citation><mixed-citation xml:lang="en">Soehnlein O., Kai-Larsen Y, Frithiof R. et al. Neutrophil primary granule proteins HBP and HNP1-3 boost bacterial</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">phagocytosis by human and murine macrophages. J Clin Invest 2008; 118: 10: 3491-3502.</mixed-citation><mixed-citation xml:lang="en">phagocytosis by human and murine macrophages. J Clin Invest 2008; 118: 10: 3491-3502.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Kanda N., Hau C.S., Tada Y. et al. Decreased serum LL-37 and vitamin D3 levels in atopic dermatitis: relationship between IL-31 and oncostatin M. Allergy 2012; 67: 6: 804-812.</mixed-citation><mixed-citation xml:lang="en">Kanda N., Hau C.S., Tada Y. et al. Decreased serum LL-37 and vitamin D3 levels in atopic dermatitis: relationship between IL-31 and oncostatin M. Allergy 2012; 67: 6: 804-812.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Leung T.F., ChingK.W., Kong A.P. et al. Circulating LL-37 is a biomarker for eczema severity in children. J Eur Acad Der-matol Venerol2012; 26: 4: 518-522.</mixed-citation><mixed-citation xml:lang="en">Leung T.F., ChingK.W., Kong A.P. et al. Circulating LL-37 is a biomarker for eczema severity in children. J Eur Acad Der-matol Venerol2012; 26: 4: 518-522.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Mallbris L., Carlen L., Wei T. et al. Injury downregulates the expression of the human cathelicidin protein hCAP18/LL-37 in atopic dermatitis. Exp Dermatol 2010; 19: 5: 442-449.</mixed-citation><mixed-citation xml:lang="en">Mallbris L., Carlen L., Wei T. et al. Injury downregulates the expression of the human cathelicidin protein hCAP18/LL-37 in atopic dermatitis. Exp Dermatol 2010; 19: 5: 442-449.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Ballardini N., Johansson C, Lilja G. et al. Enhanced expression of the antimicrobial peptide LL-37 in lesional skin of adults with atopic eczema. Br J Dermatol 2009; 161: 1: 40-47.</mixed-citation><mixed-citation xml:lang="en">Ballardini N., Johansson C, Lilja G. et al. Enhanced expression of the antimicrobial peptide LL-37 in lesional skin of adults with atopic eczema. Br J Dermatol 2009; 161: 1: 40-47.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">HowellM.D., GalloR.L., BoguniewiczM. etal. Cytokine milieu of atopic dermatitis skin subverts the innate immune response to vaccinia virus. Immunity 2006; 24: 341—348.</mixed-citation><mixed-citation xml:lang="en">HowellM.D., GalloR.L., BoguniewiczM. etal. Cytokine milieu of atopic dermatitis skin subverts the innate immune response to vaccinia virus. Immunity 2006; 24: 341—348.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">HowellM.D., WollenbergA., GalloR.L. etal. Cathelicidin deficiency predisposes to eczema herpeticum. J Allergy Clin Immunol 2006; 117: 836-841.</mixed-citation><mixed-citation xml:lang="en">HowellM.D., WollenbergA., GalloR.L. etal. Cathelicidin deficiency predisposes to eczema herpeticum. J Allergy Clin Immunol 2006; 117: 836-841.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">European Task Force on Atopic Dermatitis. Severity scoring of atopic dermatitis the SCORAD index. Consensus report of the European task force on atopic dermatitis. Dermatology 1993; 186: 1:23-26.</mixed-citation><mixed-citation xml:lang="en">European Task Force on Atopic Dermatitis. Severity scoring of atopic dermatitis the SCORAD index. Consensus report of the European task force on atopic dermatitis. Dermatology 1993; 186: 1:23-26.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Dillon S.R., Sprecher C, Hammond A. et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol 2004; 5: 7: 752-760.</mixed-citation><mixed-citation xml:lang="en">Dillon S.R., Sprecher C, Hammond A. et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol 2004; 5: 7: 752-760.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Brogden N.K., Mehalick L., Fischer C.L. et al. The emerging role of peptides and lipids as antimicrobial epidermal barriers and modulators of local inflammation. Skin Pharmacol Physiol 2012; 25: 4: 167-181.</mixed-citation><mixed-citation xml:lang="en">Brogden N.K., Mehalick L., Fischer C.L. et al. The emerging role of peptides and lipids as antimicrobial epidermal barriers and modulators of local inflammation. Skin Pharmacol Physiol 2012; 25: 4: 167-181.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
